Hartkopf, Andreas D. and Brucker, Sara Y. and Taran, Florin-Andrei and Harbeck, Nadia and von Au, Alexandra and Naume, Bjorn and Pierga, Jean-Yves and Hoffmann, Oliver and Beckmann, Matthias W. and Ryden, Lisa and Fehm, Tanja and Aft, Rebecca and Sola, Montserrat and Walter, Vincent and Rack, Brigitte and Schuetz, Florian and Borgen, Elin and Ta, Minh-Hanh and Bittner, Ann-Kathrin and Fasching, Peter A. and Ferno, Marten and Krawczyk, Natalia and Weilbaecher, Katherine and Margeli, Mireia and Hahn, Markus and Jueckstock, Julia and Domschke, Christoph and Bidard, Francois-Clement and Kasimir-Bauer, Sabine and Schoenfisch, Birgitt and Kurt, Ayse G. and Wallwiener, Markus and Gebauer, Gerhard and Klein, Christoph A. and Wallwiener, Diethelm and Janni, Wolfgang and Pantel, Klaus (2021) Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. EUROPEAN JOURNAL OF CANCER, 154. pp. 128-137. ISSN 0959-8049, 1879-0852
Full text not available from this repository. (Request a copy)Abstract
Purpose: Presence of disseminated tumour cells (DTCs) in the bone marrow (BM) has been described as a surrogate of residual disease in patients with early breast cancer (EBC). PADDY (Pooled Analysis of DTC Detection in Early Breast Cancer) is a large international analysis of pooled data that aimed to assess the prognostic impact of DTCs in patients with EBC. Experimental design: Individual patient data were collected from 11 centres. Patients with EBC and available follow-up data in whom BM sampling was performed at the time of primary diagnosis before receiving any anticancer treatment were eligible. DTCs were identified by antibody staining against epithelial cytokeratins. Multivariate Cox regression was used to compare the survival of DTC-positive versus DTC-negative patients. Results: In total, 10,307 patients were included. Of these, 2814 (27.3%) were DTC-positive. DTC detection was associated with higher tumour grade, larger tumour size, nodal positivity, oestrogen receptor and progesterone receptor negativity, and HER2 positivity (all p < 0.001). Multivariate analyses showed that DTC detection was an independent prognostic marker for overall survival, disease-free survival and distant disease-free survival with hazard ratios (HR) and 95% confidence intervals (CI) of 1.23 (95% CI: 1.06-1.43, p = 0.006), 1.30 (95% CI: 1.12 e1.52, p < 0.001) and 1.30 (95% CI: 1.08-1.56, p = 0.006), respectively. There was no association between locoregional relapse-free survival and DTC detection (HR 1.21; 95% CI 0.68-2.16; p = 0.512). Conclusions: DTCs in the BM represent an independent prognostic marker in patients with EBC. The heterogeneous metastasis-initiating potential of DTCs is consistent with the concept of cancer dormancy. (C) 2021 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROGNOSTIC VALUE; PRIMARY SURGERY; MICROMETASTASIS; RECURRENCE; METASTASIS; EXPRESSION; SURVIVAL; SUBTYPES; RISK; Early breast cancer; Prognosis; Disseminated tumour cells; Bone marrow; Micrometastases; Tumour staging |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für experimentelle Medizin und Therapieverfahren |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Sep 2022 13:57 |
| Last Modified: | 27 Sep 2022 13:57 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48110 |
Actions (login required)
 |
View Item |
